Introduction
Medical technologies -comprising medical devices, pharmaceuticals, and diagnostic and treatment methods -are the cornerstone of modern medicine. While some have contributed to substantial improvements in medical outcomes and care, others may even jeopardise patients' safety (Rye and Kimberly 2007) . It often takes years to distinguish the latter from the former and to determine their performance in routine practice (Callea et al. 2017 ). Due to considerable efforts and risks linked to research and development of medical technologies, new products are often more expensive than existing alternatives and are considered a decisive factor for high health expenditures (Willemé and Dumont 2015) . Public health considerations on new technologies thus relate to the triangle of balancing patient access, safety and quality, and price setting. Worldwide, policy makers on statutory or insurance level, depending on the respective health system, are therefore responsible to weigh the potential benefits of ensuring timely access to new medical technologies against the risks of doing so in terms of safety and (cost-)effectiveness (Sorenson and Drummond 2014; Martelli and van den Brink 2014) . The evaluation of a technology's cost-effectiveness allows for clear decion making in the case of increased effectiveness and decreased or equal costs compared to comperators (or even equal effectiveness and decreased costs). However, reimbursement decisions are more complex and depend on certain health system principles, if technologies show an increased effectivesness and higher costs. (Black 1990; Drummond et al. 2015) . The reimbursement of technologies therefore plays a pivotal role for technology utilisation in health care while the particular design of the regulation depends on the kind of technology and usually differs between ambulatory and inpatient care.
Overall, the regulations on technology utilisation and coverage tend to facilitate an adoption in inpatient care, leading a majority of new technologies to enter the health system through Reimbursement of New Technologies in DRG systems 4 the inpatient sector (Sorenson and Kanavos 2011) . Hospitals have the highest share of expenditures in most health systems (Hatz et al. 2017) , making technology adoption in inpatient care highly relevant from a system perspective. However, the immediate decision on the utilisation of respective medical technologies in inpatient care is taken on hospital level, where the seemingly same conditions cause some providers to adopt a new technology but others do not Kanavos 2011, Greenhalgh et al. 2004; Torbica and Cappellaro 2010) . High expenditures and increasing financial pressures such as prospective payment systems have led to an increased economic pressure for hospitals. A variety of studies have explored incentives of prospective payment systems and their effects on technology adoption while controlling for hospital characteristics. Results suggest that DRG payments incentivise hospitals to utilise those technologies that lead to lower costs per patient, while they negatively affect cost increasing new technologies (Romeo et al 1984;  Kesteloot and Voet 1998; Lee and Waldman 1985; Scheller-Kreinsen, Quentin, and Busse 2011) .
With the aim to balance these financial disincentives for technologies that are currently not covered by health insurances − due to the time lack when introducing technologies in DRGsystems − policy stakeholders use additional payment instruments to finance certain innovative technologies cost-neutrally. Studies investigating the utilisation of innovation payments in individual countries showed that these payments are overall correlated with adopting innovations (Bech et al. 2009; Bäumler 2013; Sorenson, Drummond, and Wilkinson 2013; Wilkinson and Drummond 2014) . To explore the effect of innovation payments, most of these studies investigate the uptake of one specific technology by the respective hospital departments in a certain region. However, many innovation payments are not paid to every hospital offering the service, but only to some providers based on negotiations. This is especially the case for separate payments and funding for cost outliers Reimbursement of New Technologies in DRG systems 5 (Scheller-Kreinsen, Quentin, and Busse 2011) . As most of the previous studies analysed data regarding one medical device in one indication, our study evaluates a nationwide data set comprising all acute hospitals and the innovation payments for all diagnoses. More precisely, we aim at identifying factors at hospital and state levels that are associated with the agreement of innovation payments in German acute inpatient care as organisations are placed within special environments.
Background: Innovation payments in Germany
Hospitals in Germany are permitted to use a newly approved technology before its benefits have been systematically assessed. This does not mean, however, that they will be reimbursed for its use. It takes approximately three years until a new technology is integrated in the DRG classification depending on the time when a new procedure code is established and depending on data availability to create a new DRG (Federal Association of Statutory Health Insurance Funds 2016). Recognising that this time lag could hinder the adoption of potentially beneficial new technologies, policy-makers in Germany -as in many countries with DRG systems -have developed a system of innovation payments to provide additional funding for some of these technologies, if the price is above the existing DRG tariffs in inpatient care (Levaggi, Moretto, and Pertile 2014; Scheller-Kreinsen, Quentin, and Busse 2011; Sorenson et al. 2015) . This system was established in 2005 and involves socalled 'NUB payments,' named after the German acronym for 'New Diagnostic and Treatment Methods' (Neue Untersuchungs-und Behandlungsmethoden, Section 6(2) KHEntgG, Hospital Payment Act). From an international perspective, NUB payments can be classified as payments that are separate from the DRG system, involve additional funding (i.e., are paid on fee-for-service basis) and are negotiated locally (Sorenson, Drummond, and Wilkinson 2013; Scheller-Kreinsen, Quentin, and Busse 2011) . We will refer to NUB payments as 'innovation payments' due to internationally different terms.
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The process to receive the innovation payment consists of two-steps. In a first step, a hospital submits a request to the German Institute for the Hospital Remuneration System (InEK, Institut für das Entgeltsystem im Krankenhaus). In its request, the hospital describes (1) the new technology and the features making it beneficial for patients, (2) the patients being treated, (3) additional staff and material costs and (4) the reason why the costs of the new technology are not appropriately covered by existing DRG tariffs. If the InEK decides that the technology satisfies the criteria for innovation payments, it designates the technology 'Status 1.' In a second step, the hospital may subsequently negotiate a payment with representatives of the health insurances (Institut für das Entgeltsystem im Krankenhaus 2015). This can take place as part of, or separately from, the annual budget negotiations between the hospital and the health insurances in the state within which the hospital is located. Health insurances are, however, not obliged to agree on a payment. The negotiated budget and innovation payments are valid for all insured patients treated at that hospital; this includes all statutory health insurances (SHI) as well as all private health insurances (Loskamp et al. 2017 ). Henschke et al. give a detailed introduction into this regulatory pathway (Henschke et al. 2010 ).
Innovation payments in Germany have received little research attention. To date, two commercial reports have used questionnaires and expert interviews to explore the importance hospitals attach to innovation payments. One of these reports, commissioned by the German Medical Technology Association (BVMed), concluded that primarily university hospitals, large hospitals and hospitals with a medical specialisation considered innovation payments as relevant funding source. The authors estimated that 40 per cent of the payment requests that received approval for negotiations ultimately agreed a payment successfully with the health insurances (Blum and Offermanns 2009) . The authors of the second report commissioned by Pfizer Pharma GmbH, assessed based on a qualitative survey that Reimbursement of New Technologies in DRG systems 7 hospitals valued innovation payments not only for financial reasons but as a marketing instrument for hospitals' innovativeness. Based on these findings, innovation payments were suggested to be especially relevant for large non-university hospitals (Wilke 2007 ).
However, we were unable to identify any studies that analysed secondary countrywide data to explore which factors might affect the likelihood of a hospital and health insurances contractually agreeing innovation payments.
Theoretical framework
Particularly in times of an increasing pace of innovations technology adoption is a carefully considered decision (Lettieri and Masella 2009 ). Decision making is exacerbated by financial pressures based on the introduction of innovation payments. Identifying factors that explain differences in hospitals' adoption behaviour plays an important role in adoption research (Greenhalgh et al. 2004; Torbica and Cappellaro 2010; Sorenson and Kanavos 2011) . According to our specific aim that focuses on examining hospitals'decision with regard to aggreeing innovation payments, Rogers' Innovation-Diffusion Theory, used in a variety of research fields, is used as theoretical framework. It may be one of the most influential work to understand the comprehensive structure of adopting innovations, identifying three main sources that influence the adoption of innovations, namely the perception of innovation characteristics, the adopter characteristics and contextual determinants also known as environmental determinants (Rogers 2003 (Rogers , first published in 1962 . Rogers additionally defines the steps of the decision making process as knowledge, persuasion, decision, implementation and confirmation (Rogers 2003) . In the context of large complex organisations this is accompagnied by the division of duties as each step of technology adoption and assimilation may be executed by different people (Sáenz-Royo, Gracia-Lázaro, and Moreno 2015), such as the treating physicians, chief physicians, hospital managers and controlling personnel (Kimberly and Evanisko 1981 (Greer 1985) . This is an important issue when focussing on different kinds of technologies. However, when focusing on medical technologies that are utilised in direct patient care -so called 'medical-individualistic' technologies in Greer's terms and that additionally exhibit similar characteristics such as being not adequately captured by DRG systems due to their novelty, technology characteristics might be neglected. We therefore focus on the role of organisational and environmantal determinants that play an essential role in technology adoption of hospitals (McCullough 2008) .
Organisational determinants of adopting innovations have been widely investigated.
Previous research showed that internal organisational characteristics are associated with the adoption of innovations (Kimberly and Evanisko 1981 , Greenhalgh 2004 , Rye and Kimberly 2007 , Varabyova et al. 2017 . From the perspective of restricted resources, larger hospitals tend to have more complex resources in terms of technical equipment available in that hospital, and a better technological know-how (Weng et al 2011) . Additionally, there might be differences in the hospital's stance on new technologies. Large hospitals generally employ more administrative staff and have a separate finance and performance directorate (Blank and Valdmanis 2015) . Considering their regional importance, they may have a stronger negotiating position than smaller hospitals and may therefore be more successful at agreeing innovation payments.We therfore hypothesise that agreements on innovation payments will be positively influenced by hospital size.
Being a university hospital is likely to be associated with a greater willingness to adopt and develop new technologies given their teaching and research mission (Weng et al. 2006) .
With regard to the utilization rate of new technologies, Mitchell and colleagues found that
Reimbursement of New Technologies in DRG systems 9 the proportion of MR imaging was higher in teaching hospitals compared to non-teaching hospitals (Mitchell et al. 2002) . Furthermore, evidence suggests that university hospitals may have a strong negotiating position with the health insurances (White, Reschovsky, and Bond 2014; Bäumler 2013; Blum and Offermanns 2009) . We therefore hypothesise that aggreements on innovation payments will be positively associated with the university status of a hospital.
As the mission of an organisation may affect strategic decision making with regard to the adoption of innovative technologies, for profit organisations are the most market-orientated providers. Consequently, they may have higher incentives to use new technologies with the aim of attracting more patients (Banaszak-Holl 1996) . In the context of successful agreements on innovation payments, we hypothesise that for-profit hospitals have greater incentives to agree innovations payments due to their market orientation. However, evidence on the relationship between hospital ownership and the uptake of new technologies is severity are also considered to be specialised (Farley and Hogan 1990; Zwanziger, Melnick, and Simonson 1996; Bonastre et al. 2014 ). There are intensive discussions in scientific research as the first definition might not adequately explain specialisation, e.g. when using the hospital level. University hospitals may have many cases in one clinical field while their share of cases compared to all other cases might be small. We therefore expect a negative association for specialisation in terms of concentration which is defined according to the range of services. Regarding a hospital's specialisation in terms of a high degree of severity, one can assume that the uptake of new technologies tends to be quicker and more comprehensive in university hospitals compared to a general hospital, making it worthwhile for the former to apply for extra funding. We hypothesise that a high severity level is associated with agreeing innovations payments.
Environmental determinants
In addition, a high degree of competition in the vicinity of a hospital may act as an incentive to adopt new technologies (Castro et al. 2014; Blank and Valdmanis 2015) . Many studies also analyse effects of competition on hospitals' patient volume, average length of stay, costs of care, and efficiency (Robinson and Luft 1985 , Schmid and Ulrich 2012 , Tiemann et al. 2012 . The regulatory and competitive environment in the German hospital sector has been part of consolidation and reorganisation processes (Schmid and Ulrich 2012) .
Overcapacities in urban areas result in increasing competitive pressure (Tiemann and Schreyögg 2009 ). Therefore, it is likely to assume that high competition leads to successful negotiations of innovation payments to further increase hospitals' competitiveness in terms of attracting more patients. Robinson and Luft concluded that higher costs of hospitals operating in highly competetive areas have been a result of higher demand in wealthy areas for technologically sophisticated and expensive clinical medicine (Robinson and Luft 1985) .
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Lastly, the bed occupancy rate is a measure of the overall supply of and demand for hospital services within a state (Dayhoff and Cromwell 1993) . It is the share of occupied inpatient bed days divided by the available inpatient bed days over a year in each state. With regard to innovation payments, hospitals in a state with a low bed occupancy rate might have a greater incentive to offer additional services compared to a hospital with a high occupancy rate and thus request more funding.
While German innovation payments are regulated by federal law, we assume they are implemented differently in each of Germany's 16 federal states. Indeed, decisions on hospital planning and financing are the responsibility of the states rather than of the federal government. Hospitals' operational costs are covered primarily by DRG payments made by statutory and private health insurers while capital investment is primarily financed from state budgets. Furthermore, the representatives of health insurances responsible for negotiating innovation payments differ between states. In short, hospitals in Germany operate within a state-specific financial and political context. We hypothesise that the variation in hospitals agreeing innovation payments can in part be explained by hospitals being clustered in the 16 states in Germany because of distinct financial and political circumstances.
With these points in mind, we hypothesise that: a) the odds of agreeing innovation payments with health insurances vary considerably among hospitals; b) this variation can be explained in part by hospital characteristics; and c) in part by hospitals being clustered in the 16 states in Germany because of distinct financial and political circumstances.
Materials and methods

Data
We conducted an empirical analysis of all acute hospitals operating within the G-DRG system. The data set was compiled by the Scientific Institute of the AOK (WIdO, Wissenschaftliches Institut der AOK) as an appendix to its annual hospital report in 2015 (Klauber et al. 2015) . The data stem mainly from the annual hospital budget agreements.
The WIdO supplemented this data set with data from quality assurance records and e-mails that the health insurances must send to InEK to inform it that an innovation payment has been agreed.
The data set encompasses all acute hospitals that treat patients insured by health insurancei.e. hospitals forming part of the hospital plans of the states and hospitals with provision contracts. In the data, a hospital is defined as the entity with which a budget agreement has been made. In cases where a chain or network of hospitals within one state is registered as one institution (i.e., with just one institutional code), it is considered to be one hospital. We obtained data on variables at the state level from the German Federal Statistical Office. All data are presented for the year 2013. We used Stata 12.1 to estimate our regression model.
Model specification
The outcome variable in our statistical model was dichotomous, assuming a value of 1 if one or more innovation payments were successfully negotiated between a hospital and the health insurances in 2013 and 0 otherwise. We undertook a multilevel analysis with hospitals clustered in states to consider the distinct financial and political contexts within which hospitals operate in a state. Based on the dimensions relevant for technology adoption, we considered relevant covariates corresponding to the organisational and the environmental Reimbursement of New Technologies in DRG systems 13 dimensions. We estimated the following explanatory variables measured on hospital and state level, derivered from the framework described above (see Table 1 ). (Bölt et al. 2012 ) by including two dummy variables, one for not-for-profit and one for private for-profit ownership, with public ownership as the reference category.
Since specialisation is not observable but needs to be interpreted from other data, there have been various attempts to find proxy variables to measure specialisation: The information theory index (ITI) and the gini coefficient of the hospital's major diagnostic categories or DRGs consider a hospital specialised when it treats a large share of cases in one field, focussing on the relative number of patient cases ( would be considered unspecialised (wide range of services). In contrast, a Gini coefficient of 1 would indicate a maximum degree of specialisation as all services would be assigned to one base DRG. To account for (II) a hospital's level of severity we assume that hospitals with a higher case-mix index have a higher level of sophistication. We thus measure this as distance of the hospital's case mix index deviating from the state mean (≥+20%, 10% to 19.99%, 0% to 9.99%, 0% to -9.99%, -10% to -19.99%, <-20%).
In addition, the degree of competition in commercial markets is measured by the use of the Herfindahl-Hirschman Index (HHI). By summing the squared market shares of all hospitals within a radius of 10 kilometres, the HHI represents not only the number of competitors within a market but also "the equity of distribution of market share" (Sethi et al. 2013 ). The HHI ranges from 0 (highly competitive) to 1 (monopoly).
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Lastly, the bed occupancy rate is reflected by the share of occupied inpatient bed days divided by the available inpatient bed days over a year in each state.
Statistical analysis
We estimated two-level logistic regression models with state-level fixed effects (random intercept models) to consider clustering of hospitals within states. State-level variance in agreed innovation payments was assessed by estimating an unconditioned model (null model). It may be written as:
( 1) where is the dependent variable (subscript i referring to the hospital and subscript j to the state), ß o is the intercept and u j the state-level random effect, assumed to be independent from one another and normally distributed with a mean of zero.
In the next step, we added the explanatory variables to the model:
where ß o is the intercept, ß 1 -ß 6 are hospital parameters and ß 7 is a state parameter associated with the covariates, and u j the random error for the state level. We conducted the Hausman test with the bed occupancy variable as random effect to determine that the fixed effect does not capture a part of the bed occupancy. According the results do not justify using random effects. The goodness of fit of the models was compared using the likelihood ratio test, estimating how much more probable the data was in the fitted model compared to the null model.
Results
Descriptive statistics
Our analysis included 1,358 hospitals in Germany, for which we had complete data on the chosen variables. Of all the hospitals in our sample, 2.7 per cent had university status. The most common hospitals were those with 200 to 499 beds (37.2 per cent) and with not-forprofit ownership (41.3 per cent). Table 2 gives a summary of the descriptive statistics. 
Factors that explain the agreement of innovation payments
We estimated a null model (Model I) first to test our observation of clustering on state level.
The estimate for the intercept produces a mean of 0.38 (95% CI 0.18-0.82) and the intraclass-correlation coefficient, calculated as the ratio of the between-variance to the total variance, is 0.042. This coefficient suggests that observations of hospitals within the same region are not fully independent from one another but clustered in states. As even small levels of dependence can lead to biased results (Cohen 2010) , we chose to investigate variation between the states in our further models by including state-specific explanatory variables. We added the hospital and state variables into the analysis in the next step (Model II). The detailed results of our two regression models are provided in Table 3 .
When the other variables were held constant, the status as university hospital was associated with an odds ratio of 4.30 (95% CI 1.00-18.47) compared to non-university hospitals.
Furthermore, large hospitals had greater odds of agreeing innovation payments compared to small hospitals. The odds ratio rose as the number of beds increased, reaching 30.35 (95% CI 8.01-115.01) for hospitals with at least 1000 beds compared to hospitals with fewer than 50 beds (reference). The odds of agreeing innovation payments were lower for public hospitals (0.69, 95% CI 0.47-1.02) and slightly lower for private for-profit hospitals (0.96, 95% CI 0.63-1.47) than for not-for-profit hospitals. The Gini coefficient of base DRGs (OR 0.38; 95% CI 0.24-0.59 second quintile compared to first quintile) suggests that the odds of agreeing innovation payments decreases with increasing centralisation in services. Opposed to this, we estimate a positive correlation between hospitals with a higher case-mix index than state mean and the chance of successfully negotiating innovation payments. Estimating the influence of competition and market share on the agreement of innovation payments resulted in an odds ratio of 0.43 (95% CI 0.24-0.78).
On state level, the bed occupancy rate was also negatively associated with agreeing innovation payments. The estimated odds ratio of 0.96 (95% CI 0.83-1.11) suggests that the odds of agreeing innovation payments decreases by 0.04 for each per cent that the bed occupancy rate increases. Note: *** p<0.001, ** p<0.01, * p≤0.05
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Discussion
One criterion for the success of health systems is their ability to innovate. Health policy making thus balances patient access, safety and quality of innovative health technologies, based on coverage decisions and price setting mechanisms. The implementation of temporary innovation payments aimed at balancing the disincentive of prospective payment systems to use new more expensive technologies compared to those integrated in the current DRG system . In order to assess in how far policy making achieves the aim to bridge the gap between the introduction of a new medical technology and its reimbursement through DRGs, we examined hospital and state variables that might be associated with receiving innovation payments. Each variable is assigned to the organisational and environmental dimension of Rogers' framework (Rogers 2003) .
However, variables of the product dimension which are also a part of Rogers' framework were not included in analyses as technologies concerned exhibit similar characteristics such as being not adequately captured by DRG systems due to their novelty.
The results show that hospitals with certain characteristics of the organisational and environmental dimension have a higher likelihood to access innovation payments as additional source of financing than others. In accordance with literature on this subject, a substantial share of the variance was explained on hospital level and a smaller one on state level. We found that hospitals had greater odds to agree innovation payments if they were large, had university status and were located in a region with high competition, which is consistent with previous studies (Bäumler 2013; Bech et al. 2009; Blum and Offermanns 2009 Nolting et al. 2011) .
One explanation may be that innovation payments serve as a marketing instrument, allowing hospitals to stand apart from their regional competitors. Because it has been an explicit political goal to foster competition in the German health system, these effects can be classified as intended consequences of the payment instrument (Knieps 2009 ).
We hypothesised that when a hospital serves as a specialist centre for a certain diagnosis, this specialisation might be linked to the use of new technologies. Our estimations suggest that the odds of agreeing innovation payments were lower for hospitals with a narrow range of services (i.e. high concentration of cases). One reason may be that a centralisation of a hospital's services on very few DRGs entails that there are only few innovation payments eligible for funding. There may be years in which no innovation payment exists for this area of specialisation. However, this information is not included in our data set. As the Gini coefficient only focuses on centralisation, hospitals with a wide range of services but with a high level of severity in some of their fields may be specialised despite a low Gini coefficient, such as some university hospitals. We thus also estimated the effect of hospitals' level of severity through the hospital case mix index as distance from the state mean.
Hospitals treating more severe patient cases are more likely to agree innovation payments.
Interestingly, after adjusting for case-mix, the chance to agree innovation payments is Besides these results, our study has certain limitations regarding the data set. First, regarding the dependent variable, a more robust analysis would be possible if more details on the number of technologies accepted for payments were available. Additionally, details on the number of innovations payments per hospital, the number of applications per hospital, and the process and outcomes of hospitals' annual budget negotiations would contribute to an analysis considering more specific variables. However, these data are not publicly available.
Nevertheless, to our knowledge, this data set is the best available resource covering a nationwide data set of innovation payments. Furthermore, it is the first study using a nationwide data set that includes all hospitals being allowed to negotiate innovation payments with health insurers, i.e. all technologies assessed positively in the process of innovations payment are included. While it is unlikely that a hospital would incorrectly record to have received a payment when it had not, it is conceivable that the receipt of an innovation payment is not always included in a hospital's records of its main budget negotiations because innovation payments can be agreed outside of these. To correct for this, the WIdO used data from quality assurance records and the e-mails that health insurances must send to InEK to inform it that innovation payments have been agreed with a hospital to verfify the information on innovation payments. Based on these limitations and based on the fact that health insurances are not obliged to negotiate innovation payments, our outcome variable captures two steps: (1) a hospital's successful request to InEK allowing it to negotiate a payment and (2) the successfully negotiation of a payment with the health Reimbursement of New Technologies in DRG systems 24 insurances. Lastly, due to the limitations of the data set, we were unable to consider interactions beween different individuals within the entity of hospitals as an organisation.
Since most countries with DRG systems use some form of time-limited innovation payments to encourage innovation and improve access to new technologies, we recommend that similar studies be conducted in other countries, preferably using data from all hospitals and all diagnoses, to research the matter in other prospective payment systems. As innovation payments are time-limited and most new technologies are integrated into the DRG system over time by splitting DRGs or introducing supplementary payments, further studies should investigate the link between innovation payments and permanent reimbursement in relation to the technology's benefits.
Conclusion
Evidence shows that remuneration systems such as the DRG system affect decision making of hospitals. In order to balance timely utilisation of new technologies and cost coverage, policy makers use temporary innovation payments to compensate disincentives inherent in the DRG system. Our findings shed light on the effect of hospital and state characteristics for agreeing innovation payments in German inpatient care. We thereby reveal implicit incentives of the reimbursement mechanism. The results might be of interest for the German government as well as for stakeholders in the context of prospective payment systems. 
